参考文献
1.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Soft Tissue Sarcoma Version 1.2019— December 19,2018.
2.American Joint Committee on Cancer (AJCC) Cancer Staging System (8th ed.,2017).
3.Gundle KR,Kafchinski L,Gupta S,et al.Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection.J Clin Oncol 2018, 36:704-709.
4.Berry V,Basson L,Bogart E,et al.REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.Cancer 2017, 123:2294-2302.
5.MacNeill AJ,Miceli R,Strauss DC,et al.Postrelapse outcomes after primary extended resection of retroperitoneal sarcoma:A report from the Trans-Atlantic RPS Working Group.Cancer 2017, 123:1971-1978.
6.Tap WD,Jones RL,Van Tine BA,et al.Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma:an openlabel phase 1b and randomised phase 2 trial.Lancet 2016, 388:488-497.
7.Albertsmeier M,Rauch A,Roeder F,et al.External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma:A Systematic Review and Meta-Analysis.Ann Surg Oncol 2018, 25:754-767.
8.Gingrich AA,Bateni SB,Monjazeb AM,et al.Neoadjuvant Radiotherapy is Associated with R0 Resection and Improved Survival for Patients with Extremity Soft Tissue Sarcoma Undergoing Surgery:A National Cancer Database Analysis.Ann Surg Oncol 2017, 24:3252-3263.
9.Janssen ML,van Broekhoven DL,Cates JM,et al.Metaanalysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis.Br J Surg 2017, 104:347-357.
10.Ecker BL,Peters MG,McMillan MT,et al.Implications of Lymph Node Evaluation in the Management of Resectable Soft Tissue Sarcoma.Ann Surg Oncol 2017, 24:425-433.
11.Young RJ,Litiere S,Lia M,et al.Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy:a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.Acta Oncol 2017, 56:1013-1020.(https://www.daowen.com)
12.Santti K,Beule A,Tuomikoski L,et al.Radiotherapy in desmoid tumors :Treatment response,local control,and analysis of local failures.Strahlenther Onkol 2017.
13.Naghavi AO,Fernandez DC,Mesko N,et al.American Brachytherapy Society consensus statement for soft tissue sarcoma brachytherapy.Brachytherapy 2017, 16:466-489.
14.Mullinax JE,Kroon HM,Thompson JF,et al.Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma.J Am Coll Surg 2017, 224:635-642.
15.Savina M,Le Cesne A,Blay JY,et al.Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting:the METASARC observational study.BMC Med 2017, 15:78.
16.Neuwirth MG,Song Y,Sinnamon AJ,et al.Isolated Limb Perfusion and Infusion for Extremity Soft Tissue Sarcoma:A Contemporary Systematic Review and Meta-Analysis.Ann Surg Oncol 2017, 24:380
17.Italiano A,Di Mauro I,Rapp J,et al.Clinical effect of molecular methods in sarcoma diagnosis (GENSARC):a prospective,multicentre,observational study.Lancet Oncol 2016, 17:532-538.
18.Kachare SD,Brinkley J,Vohra NA,et al.Radiotherapy associated with improved survival for high-grade sarcoma of the extremity.J Surg Oncol 2015, 112:338-343.
19.Chudgar NP,Brennan MF,Tan KS,et al.Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma? Ann Thorac Surg 2017, 104:1837-1845.
20.Kainhofer V,Smolle MA,Szkandera J,et al.The width of resection margins influences local recurrence in soft tissue sarcoma patients.Eur J Surg Oncol 2016, 42:899-906.
21.Kollar A,Jones RL,Stacchiotti S,et al.Pazopanib in advanced vascular sarcomas:an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.Acta Oncol 2017, 56:88-92.
22.Le Cesne A,Blay JY,Domont J,et al.Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS):a randomised phase 2 trial.Lancet Oncol 2015, 16:312-319.